Diagnostic Assays
Learn more about our assays for molecular diagnostics
Our assays for molecular diagnostics can be used as part of the NEOonsite technology platform. They can be performed on a single DNA sample, additional RNA analyses are no longer necessary.
Please contact us if you are interested in using our technology for specific questions as part of your research project.
Assays for molecular diagnostics
As part of our CE-marked NEOonsite solution, NEOselect v1 and NEOliquid v1 are suitable for molecular analysis of solid tumors regardless of the indication. Analyses can be performed on routine clinical tissue samples (e.g. FFPE) with NEOselect v1 or blood with NEOliquid v1. All specified gene alterations can be detected from a single tumor DNA sample in a single analysis.
NEOselect v1 is a molecular genetic test that enables the analysis of solid tumors regardless of the indication. The analysis can be carried out on clinical tissue samples such as FFPE samples (fine needle biopsies, punches), cytologies or cryosections.
NEOselect v1 detects tumor relevant point mutations, small insertions and deletions, copy number alterations and gene fusions in oncogenes and tumor suppressors with high sensitivity.
NEOselect v1 panel of tested genes:
*Detailed information on the coverage of the respective genes can be found in the instructions for use.
The products/features (here mentioned) are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact NEO New Oncology GmbH for further details.
NEOliquid v1 is a non-invasive blood test for comprehensively analyzing circulating tumor DNA in the blood of cancer patients. Therapy-relevant point mutations, small insertions and deletions and gene fusions can be detected. In addition, NEOliquid v1 can detect copy number variations of MET, ERBB2 and EGFR in minute amounts of circulating tumor DNA.
NEOliquid v1 allows the parallel analysis of circulating tumor DNA for both the primary tumor and metastases, and can thus support the detection of tumor heterogeneity.
NEOliquid v1 panel of tested genes
*Detailed information on the coverage of the respective genes can be found in the instructions for use.
The products/features (here mentioned) are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact NEO New Oncology GmbH for further details.